VGX-1027 is primarily investigated for its potential therapeutic applications in autoimmune and inflammatory diseases. It has shown promise in preclinical studies for conditions like rheumatoid arthritis, lupus, and type 1 diabetes due to its immunomodulatory properties. The compound works by targeting specific pathways involved in the immune response, helping to reduce inflammation and prevent tissue damage. Additionally, VGX-1027 has been explored for its potential to protect against organ damage caused by ischemia-reperfusion injury, making it a candidate for use in transplantation and cardiovascular treatments. Its ability to modulate immune activity without causing significant immunosuppression makes it a promising agent for chronic inflammatory conditions. Ongoing research aims to further validate its efficacy and safety in clinical settings.